Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes

Area of Science:

• Health economics
• Pharmacoeconomics
• Chronic disease management

Background:

• Cost-effectiveness models for chronic diseases often neglect the detailed costs associated with disease progression and complications.
• Accurate long-term simulation of chronic disease development requires robust cost data.

Purpose of the Study:

• To identify and address key challenges in integrating cost data into cost-effectiveness models for chronic diseases.
• To highlight the importance of cost considerations alongside disease progression in economic modeling.

Main Methods:

• Utilized experience from developing and applying a diabetes cost-effectiveness model.
• Illustrated challenges through practical application and analysis of cost data integration.

Main Results:

• Cost data in chronic disease models are often inconsistent, sourced from varied publications without regard for functional form.
• Costs of complications receive less attention than disease progression modeling, and averted complication costs are difficult to estimate prospectively.
• Additive and multiplicative cost functions yield different cost-effectiveness ratios, with limited guidance on selection.

Conclusions:

• Standardizing cost estimates for chronic diseases could streamline modeling but necessitates careful consideration of functional forms and data sources.
• Further research and guidelines are needed to improve the accuracy and consistency of cost data in economic models for chronic diseases.